Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense (NYSE:BHVN)
· seekingalpha.com
Biohaven secures a transformative $795M global licensing deal with SK Biopharmaceuticals for its Kv7 ion channel platform, notably opakalim. Learn more about BHVN stock here.
If you are interested in keeping up-to-date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and ...